influenza
caus
consider
morbid
mortal
human
popul
worldwid
annual
outbreak
unit
state
claim
live
cost
billion
dollar
antivir
therapi
avail
emerg
human
virus
resist
oseltamivir
human
virus
resist
amantadin
rais
concern
use
antivir
vaccin
remain
effect
defens
influenza
process
vaccin
strain
select
antigen
drift
human
influenza
viru
isol
led
mismatch
vaccin
circul
viru
strain
threat
anoth
influenza
viru
pandem
continu
concern
particularli
increas
exposur
human
avian
swine
strain
influenza
viru
accur
specif
rapid
detect
quantif
influenza
viru
critic
success
develop
diagnost
test
antivir
drug
vaccin
assay
base
virusinduc
cytopath
effect
plaqu
form
unit
pfu
tissu
cultur
infecti
dose
still
commonli
use
quantifi
influenza
viru
assay
timeconsum
laborintens
antibodi
neutral
assay
use
studi
vaccin
efficaci
includ
hemagglutin
inhibit
assay
microneutr
assay
share
similar
limit
consider
effort
devot
improv
method
cellbas
antivir
influenza
drug
screen
use
colorimetr
fluorometr
readout
base
inhibit
virusinduc
cytotox
one
method
cell
viabil
assay
measur
atp
via
luciferas
luminesc
system
shown
give
compar
result
use
neutral
red
assay
cell
line
contain
viru
induc
report
gene
use
success
detect
retrovirus
human
immunodefici
viru
hiv
dna
virus
herp
simplex
viru
hsv
rna
virus
respiratori
syncyti
viru
rsv
recent
detect
system
influenza
viru
develop
base
virusinduc
report
gene
segment
virg
preliminari
studi
transient
transfect
cell
demonstr
potenti
approach
detect
quantifi
influenza
viru
use
luciferas
green
fluoresc
protein
gfp
report
gene
system
find
prompt
us
gener
perman
cell
line
use
linear
plasmid
dna
integr
host
cell
chromosom
studi
demonstr
util
cell
line
object
rapid
quantit
assay
viru
quantif
viru
neutral
assay
drug
screen
assay
appli
acronym
enzymelink
viru
inhibitor
report
assay
elvira
technolog
cell
line
elvira
flu
flu
b
diagnost
hybrid
inc
athen
oh
usa
plasmid
contain
virusinduc
report
gene
construct
describ
lutz
et
al
briefli
influenza
viru
wsn
np
genom
segment
insert
human
polymeras
promot
termin
element
plasmid
use
follow
two
partial
complementari
oligonucleotid
contain
red
blue
untransl
region
np
segment
ctttaccgatgtcactcagtgagtgattatctacc
agtgacatcggtaaagtttaaacagaaaaataccc
oligonucleotid
design
anneal
would
end
allow
ligat
bsm
bi
site
pme
restrict
site
two
utr
element
insert
report
gene
firefli
luciferas
promega
madison
wi
usa
gfp
clontech
mountain
view
ca
usa
report
gene
insert
pme
site
result
utr
plasmid
pol
promot
utr
report
gene
cassett
remov
vector
insert
vector
final
ebv
origin
replic
gene
delet
plasmid
restrict
endonucleas
ssp
spe
gener
plasmid
viru
luchyg
viru
gfphyg
similar
strategi
use
influenza
b
viru
utr
np
segment
b
yamanashi
strain
four
oligom
use
link
make
base
pair
oligonucleotid
shown
two
partial
complementari
oligonucleotid
caagtaccaataaaaagaactgaaaaatcaaagtt
taaacagcaacaaaatagacactatggctgtgatt
gtttcaatacgtttggaatgtgggtgtttactctta
tttaataagagtaaacacccacattccaaacgtat
tgaaacaatcacagccatagtgtctattttgttgc
tgtttaaactttgatttttcagttctttttattggt
redcolor
letter
b
yamanashi
np
base
blue
color
letter
b
yamanashi
np
base
influenza
viru
clone
strategi
anneal
duplex
oligonucleotid
end
allow
ligat
bsm
bi
site
pme
restrict
site
two
utr
element
insert
report
gene
renilla
luciferas
phrltk
promega
gfp
gener
plasmid
b
viru
luchyg
b
viru
gfphyg
human
kidney
cell
american
type
cultur
center
manassa
va
usa
grown
dulbecco
modifi
eagl
medium
contain
fetal
bovin
serum
mm
glutamin
lg
ml
gentamcin
co
madindarbi
canin
kidney
mdck
cell
attc
grown
medium
cell
transfect
select
elvira
flu
flu
b
cell
line
cell
plate
two
well
plate
transfect
linear
viru
luchyg
b
viru
luchyg
viru
gfphyg
b
viru
gfphyg
use
hyfect
denvil
scientif
inc
metuchen
nj
usa
accord
manufactur
instruct
incub
hour
cell
trypsin
serial
dilut
plate
transfect
cell
cultur
media
contain
lg
ml
hygromycin
b
invitrogen
corpor
carlsbad
ca
usa
coloni
observ
transfer
singl
well
plate
monolay
confluent
cell
coloni
pass
four
well
two
separ
plate
one
plate
maintain
cultur
medium
incub
one
well
coloni
plate
either
infect
influenza
viru
influenza
b
viru
use
uninfect
control
twentyfour
hour
viru
infect
luciferas
activ
gfp
fluoresc
measur
cell
coloni
high
infectedtouninfect
ratio
luciferas
gfp
activ
select
subclon
select
clone
plate
plate
averag
cell
well
cultur
medium
contain
lg
ml
hygromycin
b
obtain
isol
clonal
cell
line
virusinfect
elvira
flu
aluc
cell
lyse
analyz
firefli
luciferas
activ
use
brightglo
luciferas
assay
system
promega
elvira
flu
brluc
cell
lyse
analyz
activ
use
renilla
luciferas
assay
system
promega
verita
luminomet
turner
biosystem
sunnyval
ca
usa
use
measur
rel
light
unit
rlu
accord
manufactur
instruct
elvira
flu
agfp
flu
bgfp
cell
line
assess
report
gene
express
visual
examin
monolay
hour
postinfect
nikon
eclips
fluoresc
light
microscop
magnif
nikon
melvil
ny
usa
light
sourc
microscop
chiu
technic
corpor
king
park
ny
usa
imag
captur
qcaptur
softwar
quantit
imag
corpor
surrey
bc
canada
influenza
wsn
viru
infecti
unit
wisconsin
infecti
unit
well
incub
hour
twofold
serial
dilut
mous
antia
wsn
human
sera
respect
sera
sampl
heat
minut
prior
incub
viru
virusserum
mixtur
ad
monolay
elvira
flu
aluc
cell
grown
plate
cell
lyse
cell
lysat
analyz
luciferas
activ
hour
postinfect
per
cent
reduct
luciferas
activ
measur
rlu
well
serumtr
viru
compar
virusonli
control
calcul
reciproc
dilut
result
reduct
greater
record
neutral
titer
influenza
wisconsin
ha
unit
infecti
unit
well
incub
twofold
serial
dilut
human
sera
hour
plate
guinea
pig
red
blood
cell
rbc
colorado
serum
co
denver
co
usa
ad
virusserum
solut
mix
plate
read
minut
incub
room
temperatur
elvira
flu
aluc
mdck
cell
grown
plate
confluenc
cell
wash
serumfre
medium
phosphatebuff
salin
nine
serial
dilut
influenza
viru
made
serum
free
medium
dilut
use
inocul
well
cell
type
plate
centrifug
hour
infect
incub
co
elvira
flu
aluc
cell
lysat
analyz
luciferas
activ
hour
infect
mdck
cell
observ
cytopath
effect
cpe
day
infect
elvira
flu
aluc
well
consid
posit
viral
infect
rlu
valu
time
mean
background
rlu
valu
tissu
cultur
infecti
dose
tcid
determin
reed
muench
method
elvira
flu
aluc
cell
use
assess
inhibit
influenza
variou
concentr
amantadin
sigmaaldrich
st
loui
mo
usa
bafilomycin
cell
plate
plate
describ
incub
serial
dilut
drug
minut
amantadin
minut
bafilomycin
influenza
viru
infecti
unit
ad
well
contain
amantadin
odh
infect
cell
bafilomycin
infect
cell
plate
centrifug
hour
incub
co
hour
follow
measur
luciferas
activ
concentr
drug
reduc
rlu
compar
nodrug
control
calcul
report
ic
valu
stabl
human
kidney
cell
line
constitut
express
negativesens
rna
encod
firefli
luciferas
gene
luc
gfp
gene
flank
untransl
region
utr
np
segment
influenza
viru
wsn
utr
influenza
b
viru
b
yamanashi
gener
describ
materi
method
section
virusinduc
report
gene
cell
express
control
human
rna
polymeras
promot
termin
sequenc
human
polymeras
promot
speciesspecif
requir
parent
cell
line
human
origin
cell
line
cultur
passag
appreci
loss
induc
report
gene
express
virusinduc
report
gene
express
elvira
flu
aluc
elvira
flu
brluc
cell
line
assess
infect
influenza
b
virus
respect
high
low
moi
variou
time
infect
cell
lyse
luciferas
activ
measur
figur
graphic
display
data
reveal
classic
singl
multistep
viral
growth
kinet
time
cours
similar
infecti
viru
product
cell
result
reveal
measur
luciferas
activ
provid
valid
surrog
marker
viru
replic
viru
doserespons
perform
infect
elvira
flu
aluc
elvira
flu
brluc
cell
line
variou
amount
influenza
b
virus
measur
luciferas
activ
hour
figur
cell
line
linear
doserespons
curv
wide
dynam
rang
result
suggest
methodolog
use
accur
titer
viru
stock
next
determin
titer
stock
sever
influenza
b
viru
strain
use
elvira
flu
aluc
elvira
flu
brluc
cell
determin
titer
time
mdck
cell
use
tcid
method
includ
analysi
four
strain
highli
pathogen
avian
influenza
viru
abl
induc
luciferas
elvira
flu
aluc
cell
data
shown
shown
tabl
titer
gener
cell
line
similar
addit
cell
line
express
virusinduc
luciferas
gener
cell
line
express
gfp
follow
influenza
viru
infect
use
strategi
figur
show
absenc
gfp
express
mockinfect
cell
high
level
express
cytoplasm
influenza
virusinfect
elvira
flu
agfp
cell
influenza
b
virusinfect
flu
bgfp
cell
crossinduct
observ
cell
could
use
method
advantag
use
either
live
intact
cell
ie
cell
lyse
test
panel
influenza
viru
influenza
b
viru
isol
includ
type
elvira
flu
aluc
cell
influenza
viru
isol
induc
high
level
luciferas
signaltonois
ratio
rang
tabl
influenza
viru
trigger
luciferas
elvira
flu
brluc
cell
low
level
one
isol
influenza
b
viru
b
taiwan
induc
low
level
luciferas
two
other
induc
activ
elvira
flu
aluc
cell
background
tabl
cell
line
also
infect
panel
unrel
respiratori
virus
high
moi
twentyfour
hour
infect
luciferas
express
essenti
background
signaltonois
never
higher
two
tabl
result
figur
show
luciferas
activ
proport
viru
inoculum
suggest
system
could
appli
influenza
assay
depend
quantit
assess
viru
infect
therefor
test
use
system
titer
neutral
serum
dilut
immun
nonimmun
mous
sera
ad
fix
amount
influenza
viru
shown
figur
immun
serum
reduc
luciferas
activ
dosedepend
manner
nearli
background
level
record
titer
reciproc
lowest
dilut
serum
result
least
reduct
luciferas
compar
virusonli
control
compar
use
assay
hemagglutin
inhibit
assay
assess
neutral
titer
nine
human
sera
influenza
viru
wisconsin
five
sera
influenza
b
viru
b
shown
tabl
titer
compar
although
ident
uncommon
compar
microneutr
hi
applic
methodolog
antivir
suscept
test
also
evalu
figur
show
effect
variou
concentr
two
known
antiinfluenza
compound
virusinduc
luciferas
express
graphic
display
result
show
classic
sigmoid
curv
ic
determin
calcul
use
method
similar
result
report
literatur
amantadinesensit
influenza
strain
influenza
b
viru
resist
amantadin
reflect
lack
reduct
luciferas
express
follow
amantadin
treatment
infect
elvira
flu
brluc
cell
figur
accur
specif
rapid
identif
quantif
influenza
viru
import
compon
influenza
research
antivir
drug
discoveri
vaccin
develop
new
technolog
promot
goal
result
develop
better
drug
vaccin
control
season
influenza
hope
prevent
lessen
impact
pandem
studi
describ
success
establish
stabl
cell
line
engin
contain
influenza
virusinduc
report
gene
cell
form
basi
rapid
object
assay
use
measur
titer
infecti
viru
titer
neutral
antibodi
suscept
influenza
viru
strain
antivir
drug
concept
virg
describ
number
year
ago
first
success
appli
influenza
virus
lutz
et
al
proofofconcept
report
influenza
virusdepend
report
gene
express
demonstr
use
rna
segment
transcrib
human
polymeras
promot
contain
report
gene
flank
untransl
region
utr
influenza
nucleoprotein
np
rna
segment
unfortun
transient
episom
express
system
use
previou
work
drawback
attempt
appli
technolog
robust
reliabl
assay
could
use
industri
clinic
applic
report
gener
stabli
transform
cell
line
demonstr
cell
line
maintain
mani
passag
without
loss
phenotyp
respect
virusinduct
report
gene
also
extend
technolog
influenza
b
viru
compon
influenza
vaccin
contrib
ute
signific
morbid
mortal
mani
influenza
season
shown
number
isol
influenza
b
virus
induc
high
signaltonois
respect
cell
line
linear
doserespons
relationship
report
enzym
activ
viru
inoculum
observ
observ
allow
use
report
enzym
level
surrog
marker
viru
amount
assay
depend
know
much
viru
sampl
cours
standard
curv
must
gener
strain
mani
applic
strain
viru
known
approach
easili
appli
detect
unknown
strain
empir
assess
abil
viru
induc
report
enzym
level
perform
assess
specif
report
enzym
induct
use
panel
respiratori
virus
none
respiratori
virus
inocul
onto
cell
line
induc
signific
luciferas
activ
background
level
level
crossinduct
influenza
b
virus
induct
homolog
viru
manyfold
higher
heterolog
viru
recent
report
shown
activ
type
b
polymeras
machineri
type
promot
depend
specif
rna
segment
level
activ
differ
type
b
strain
use
plasmid
transfect
observ
type
b
polymeras
machineri
compos
homolog
subunit
function
type
promot
albeit
variabl
extent
depend
upon
segment
region
downstream
promot
sequenc
deriv
author
assess
deliveri
polymeras
gene
viru
infect
may
explain
greater
specif
observ
titrat
influenza
viru
often
perform
mdck
cell
endpoint
dilut
observ
cpe
calcul
tcid
determin
titer
stock
number
strain
influenza
viru
includ
five
strain
use
tcid
method
use
either
elvira
flu
aluc
cell
luciferas
readout
mdck
cell
cpe
readout
titer
determin
two
method
similar
despit
fact
may
differ
suscept
two
cell
line
viru
strain
test
strain
need
test
support
use
elvira
flu
aluc
cell
purpos
clear
advantag
term
reduc
time
result
eg
day
versu
day
greater
object
less
labor
titrat
neutral
antibodi
assay
potenti
benefit
use
cell
line
clear
induct
report
enzym
depend
infecti
viru
use
immun
mous
serum
demonstr
neutral
activ
antiserum
identifi
function
reduct
luciferas
activ
titer
calcul
base
inhibit
hi
assay
current
gold
standard
measur
immun
follow
vaccin
comparison
neutral
titer
two
methodolog
show
reason
correl
though
surpris
titer
ident
given
assay
measur
neutral
differ
manner
assay
describ
report
offer
number
advantag
viru
neutral
assay
base
variou
endpoint
final
appli
technolog
assess
antivir
suscept
observ
excel
doserespons
measur
luciferas
activ
versu
drug
concentr
two
antivir
compound
mechan
action
act
viru
entri
calcul
ic
valu
similar
publish
report
use
amantadinesensit
viru
strain
use
method
neuraminidas
inhibitor
howev
result
suggest
elvira
flu
aluc
cell
could
use
screen
novel
antivir
agent
quantifi
antivir
potenc
identif
new
antivir
lead
compound
depend
robust
primari
assay
highthroughput
screen
larg
librari
compound
method
also
develop
rapid
evalu
compound
antivir
activ
micropl
includ
visual
quantit
antivir
activ
base
upon
inhibit
virusinduc
cpe
less
subject
colorimetr
fluorometr
mean
cellbas
screen
potenti
influenza
antivir
measur
cpe
induc
influenza
viru
udorn
infect
mdck
cell
use
luminescentbas
celltit
glo
system
recent
describ
recent
viral
inhibit
assay
base
neuraminidas
na
activ
describ
shown
suitabl
high
throughput
screen
identifi
potenti
antivir
compound
identifi
drugresist
influenza
strain
fluorometr
chemiluminesc
na
assay
also
describ
applic
technolog
describ
report
may
also
use
primari
antivir
screen
one
advantag
readout
direct
function
viral
rna
replic
transcript
summari
engin
stabl
cell
line
contain
influenza
viru
influenza
b
virusinduc
report
gene
use
assay
object
measur
infecti
viru
titer
antibodi
neutral
titer
antivir
drug
potenc
cell
line
maintain
passag
without
loss
induc
report
enzym
activ
although
studi
need
verifi
accuraci
precis
methodolog
great
potenti
assay
replac
tradit
techniqu
